^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    13h
    Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma. (PubMed, Transplant Cell Ther)
    These findings provide a signal supporting the feasibility and safety of bendamustine-based lymphodepletion and highlight the prognostic relevance of renal function in Cilta-Cel-treated patients. While Cilta-Cel generally confers superior efficacy compared with Ide-Cel, this advantage may be attenuated in patients with moderate/severe CKD, potentially due to competing risks such as frailty, early toxicity, or impaired cellular fitness.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    cyclophosphamide • bendamustine • fludarabine IV • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel)
    3d
    DUO-CRC-NK-111: Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=48, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • GUCY2C (Guanylate Cyclase 2C)
    |
    cyclophosphamide • fludarabine IV
    3d
    Prospective Single-Arm Clinical Study of Thiotepa-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P4, N=31, Recruiting, Sun Yuqian
    New P4 trial
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    fludarabine IV • thiotepa • busulfan
    3d
    EB-DUALNK-OV: Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    3d
    Breakfree-SSc: A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (clinicaltrials.gov)
    P3, N=92, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • cyclophosphamide • nintedanib • fludarabine IV • Actemra IV (tocilizumab) • zolacaptagene autoleucel (BMS-986353)
    3d
    SOLID-NK: Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    fludarabine IV
    3d
    Phase 2 Study of Rapcabtagene Autoleucel in Myositis (clinicaltrials.gov)
    P2, N=123, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2030 --> Feb 2033 | Trial primary completion date: Jul 2029 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • rapcabtagene autoleucel (YTB323)
    3d
    NCI-2018-01752: Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P2, N=68, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • methotrexate • fludarabine IV • thiotepa • busulfan • methotrexate IV
    3d
    Haplo-Cord HSCT for AML/MDS (clinicaltrials.gov)
    P=N/A, N=180, Recruiting, Fujian Medical University Union Hospital
    New trial
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    NPM1 mutation • KIT mutation
    |
    cytarabine • cyclophosphamide • melphalan • fludarabine IV • busulfan
    4d
    A Novel Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplant in Patients Aged ≥ 40 Years Old With Severe Aplastic Anemia (clinicaltrials.gov)
    P=N/A, N=64, Not yet recruiting, Peking University People's Hospital
    New trial
    |
    cyclophosphamide • fludarabine IV
    5d
    NT-175-201: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (clinicaltrials.gov)
    P1, N=45, Recruiting, AstraZeneca | Trial primary completion date: Sep 2028 --> Jul 2029
    Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV • NT-175
    5d
    ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (clinicaltrials.gov)
    P=N/A, N=92, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting | N=30 --> 92
    Enrollment open • Enrollment change • IO biomarker
    |
    ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • Nailike (olverembatinib) • fludarabine IV